Canada’s Breast Cancer Therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 8.8% during the forecast period (2019-2028).
Canada’s breast cancer therapeutics market is estimated to grow significantly at a CAGR of around 8.8% during the forecast period. In Canada 1 in 8 women are diagnosed with breast cancer in their lifetime, and over 25,000 Canadian women diagnosed each year. Breast cancer accounts for approximately 25% of new cases of cancer and 13% of all cancer deaths in Canadian women. The factors that enable the growth of the market include the prevalence of breast cancer and the initiative by the government and private organizations. Breast cancer is the second leading cause of mortality in Canada. The incidence rate of breast cancer in Canada is increasing with the increase in years.
Market Driving Factors
An increase in the prevalence of Breast cancer, growth in awareness about the availability of cancer treatments, growing healthcare spending for cancer and the launch of technologically advanced therapeutics are predominantly driving the market growth. the advancement of cancer drug research owing to targeted therapies and personalized medicines hold promising opportunities for pharmaceutical, bio-pharmaceutical, and biotechnology companies engaged in developing cancer drugs. However, the higher cost involved in new drug development coupled with adverse effects associated with anti-cancer drug therapies is projected to restrain the growth of the Canada Breast Cancer drug market.